ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Med Arch. 2014; 68(3): 218-220


Posterior Reversible Encephalopathy Syndrome (PRES) as a Complication of Immunosuppressive Therapy in Renal Transplantation in Children

Emir Hodzic, Majda Brcic, Mirza Atic, Alma Halilcevic, Amila Jasarevic, Mirna Aleckovic-Halilovic, Davor Trojak, Nedima Atic, Snezana Zulic, Zlatan Mehmedovic, Ivana Iveljic.



Abstract
Download PDF Post

Although kidney transplantation is by far the best method of renal replacement therapy, organ receiver is still not spared of eventual toxic consequences of drugs that are in charge of keeping the transplanted kidney functional. Both calcineurin inhibitors, of which tacrolimus more often, occasionally lead to neurotoxic side effects, mostly mild and reversible and dose-dependent in nature, but they can also be very severe or even fatal. It is very important to be aware of possible neurotoxic effects, to confirm them radiologically, and to prevent or reduce drug effects on nervous system. Sometimes the reduction of dose or substitution with another drug with similar mechanism effect is sufficient to terminate the neurotoxic effects of the drug and still not jeopardize the function of transplanted organ.

Key words: Posterior reversible encephalopathy syndrome, kidney transplantation







Bibliomed Article Statistics

34
34
33
48
33
21
38
47
32
44
29
16
R
E
A
D
S

21

12

7

52

15

12

16

13

10

16

16

6
D
O
W
N
L
O
A
D
S
030405060708091011120102
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.